Acquisition – Page 2

Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma

2 months ago talkbio0Tagged Acquisition, Asarina, asset, CNS disorder, Neurosteroids, Pharma, Phase 2b, Pregnanolone, (3beta, 5alpha)-isomer, Relmada, Tourette 's syndrome

Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders

Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment

3 months ago talkbio0Tagged Acquisition, Bain Capital, carve-out, Drug Industry, Investments, Japanese language, Mitsubishi, Private Equity, Transaction

Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment

Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review

3 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Drug Industry, M&A, strategic alternatives, Zurzuvae

Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A

Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals

3 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Neurodevelopmental Disorders, Neuropsychiatry, proposal - intent, Zurzuvae

Sage Therapeutics, Biogen, Acquisition Proposal, Postpartum Depression, ZURZUVAE, Neurodevelopmental Disorders, Neuropsychiatry

Sage Therapeutics Files Lawsuit Against Biogen Following $469 Million Acquisition Offer

3 months ago talkbio0Tagged Acquisition, Biogen, Drug Industry, Neuroscience discipline

Sage Therapeutics, Biogen, lawsuit, acquisition offer, $469 million, neuroscience, pharmaceutical industry

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion to Strengthen Neuroscience Portfolio

3 months ago talkbio0Tagged Acquisition, Biological Factors, Caplyta, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Biopharmaceutical

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

3 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Bipolar Depression, Schizophrenia, Major Depressive Disorder